Anti-cytokine therapy for rheumatoid arthritis

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 207-229

  Maini, R N ^a   Taylor, P C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti TNF ; Etanercept; IL 1ra; Infliximab; Randomized trials

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-1; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034048349     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.207     Document Type: Review

References (79)

1. 1. Feldmann M, Brennan FM, Maini RN. 1996. Role of cytokines in rheumatoid arthritis. Anna. Rev. Immunol. 14:397-440
2. 2. Pincus T, Callahan LF. 1993. What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 19:123-51
3. 3. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. 1991. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum. 34:660-68
4. 4. Dayer JM, Beutler B, Cerami A. 1985. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162: 2163-68
5. 5. Dayer JM, de Rochemonteix B, Burrus B, et al. 1986. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 177:645-48
6. 6. Saklatvala J. 1986. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547-49
7. 7. Pettipher ER, Higgs GA, Henderson B. 1986. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. USA 83:8749-53
8. 8. Firestein GS, Zvaifler NJ. 1990. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 33:768-73
9. 9. Burger D, Dayer J-M. 1998. Interactions between T cell plasma membranes and monocytes. In T Cells in Arthritis, ed. P Miossec, WB van den Berg, GS Firestein, pp. 111-28. Basel/Boston/Berlin: Birkhauser. 236 pp.
10. 10. Chu CQ, Field M, Feldmann M, Maini RN. 1991. Localization of tumour necrosis factor α in synovial tissues and the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34:1125-32
11. 11. Deleuran BW, Chu CQ, Field M, et al. 1992. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor α. Arthritis Rheum. 35:1170-78
12. 12. Brennan FM, Gibbons DL, Mitchell T, et al. 1992. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur. J. Immunol. 22:1907-12
13. 13. Chu CQ, Field M, Allard S, et al. 1992. Detection of cytokines at the cartilage/ pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol. 31:653-61
14. 14. Wood NC, Dickens E, Symons JA, Duff GW. 1992. In situ hybridisation of interleukin-1 in CD14 positive cells in rheumatoid arthritis. Clin. Immunol. Immunopathol. 62:295-300
15. 15. Buchan G, Barrett K, Turner M, et al. 1988. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin. Exp. Immunol. 73:449-55
16. 16. Brennan FM, Chantry D, Jackson A, et al. 1989. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-47
17. 17. Haworth C, Brennan FM, Chantry D, et al. 1991. Expression of granulocyte-macrophage colony-stimulating factor (GMCSF) in rheumatoid arthritis: regulation by tumour necrosis factor α. Eur. J. Immunol. 21:2575-79
18. 18. Butler D, Maini RN, Feldmann M, Brennan FM. 1995. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cultures. Comparison of monoclonal anti TNFmonoclonal antibody with the IL-1 receptor antagonist. Eur. Cytokine Netw. 6:225-30
19. 19. Katsikis PD, Chu CQ, Brennan FM, et al. 1994. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J. Exp. Med. 179:1517-27
20. 20. Fava R, Olsen N, Keski-Oja J, et al. 1989. Active and latent forms of transforming growth factor β activity in synovial effusions. J. Exp. Med. 169:291-96
21. 21. Engelmann H, Aderka D, Rubinstein M, et al. 1989. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264:11974-80
22. 22. Seckinger P, Isaaz S, Dayer JM. 1988. A human inhibitor of tumor necrosis factor α. J. Exp. Med. 167:1511-16
23. 23. Cope AP, Aderka D, Doherty M, et al. 1992. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatoid diseases. Arthritis Rheum. 35:1160-69
24. 24. Malyak M, Swaney RE, Arend WP. 1993. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies: potential contribution from synovial fluid neutrophils. Arthritis Rheum. 36:781-89
25. 25. Firestein GS, Boyle DL, Yu C, et al. 1994. Synovial interleukin-1 receptor antagonist and interkleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37:644-52
26. 26. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87:2095-147
27. 27. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. 1990. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J. Clin. Invest. 85:1694-97
28. 28. Feldmann M, Brennan FM, Maini RN. 1996. Rheumatoid arthritis. Cell 85:307-10
29. 29. Williams RO, Feldmann M, Maini RN. 1992. Anti-TNF ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89:9784-88
30. 30. Piguet PF, Grau GE, Vesin C, et al. 1992. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-14
31. 31. Keffer J, Probert L, Cazlaris H, et al. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:4025-31
32. 32. van de Loo FAJ, Arntz OJ, Bakker AC, et al. 1995. Role of interleukin-1 in antigen-induced exacerbations of murine arthritis. Am. J. Pathol. 146:239-49
33. 33. Fantuzzi, G, Dinarello CA. 1996. The inflammatory response in IL-1 β deficient mice. Comparison with other cytokine-related knock-out mice. J. Leukocyte Biol. 59:489-93
34. 34. van de Loo FAJ, Joosten LAB, van Lent PLEM, et al. 1995. Role of interleukin-1 tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction: effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum. 38:164-72
35. 35. Henderson B, Thompson RC, Hardingham T, Lewthwaite J. 1991. Inhibition of interleukin-1 induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin-1 receptor antagonist. Cytokine 3:246-49
36. 36. Van den Berg WB, Joosten LAB, Helsen M, van de Loo FAJ. 1994. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95:237-43
37. 37. Lewthwaite J, Blake SM, Hardingham TE, et al. 1994. The effect of recombinant human interleukin-1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit. J. Rheumatol. 21:467-72
38. 38. Elliott MJ, Maini RN, Feldmann M, et al. 1993. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 36:1681-90
39. 39. Elliott MJ, Maini RN, Feldmann M, et al. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-10
40. 40. Paulus HE, Egger MJ, Ward JR, et al. 1990. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum. 33:477-84
41. 41. Maini RN, Elliott MJ, Long-Fox A, et al. 1995. Clinical response of rheumatoid arthritis (RA) to anti-TNFα (cA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody. Arthritis Rheum. 38:S186 (Abstr.)
42. 42. Elliott MJ, Maini RN, Feldmann M, et al. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-27
43. 43. Maini RN, Breedveld FC, Kalden JR, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (RA). Arthritis Rheum. 41:1552-63
44. 43. Maini RN, Feldmann M, Schaible T. 1999. Reply to letter. Arthritis Rheum. 42:1779-81
45. 44. Felson DT, Anderson JJ, Boers M, et al. 1995. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:727-35
46. 45. Maini RN, St. Clair E, Breedveld F, et al. 1999. Randomised phase III trial of infliximab (chimeric anti-TNFα monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate. Lancet. In press
47. 46. Moreland LW, Baumgartner SW, Schiff MH, et al. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337:141-47
48. 47. Moreland LW, Schiff MH, Baumgartner SW, et al. 1999. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 130:478-86
49. 48. Weinblatt ME, Kremer JM, Bankhurst AD, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253-59
50. 49. Rankin ECC, Choy EHS, Kassimos D, et al. 1995. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34: 334-42
51. 50. Feldmann M, Elliott MJ, Woody JN, Maini RN. 1997. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv. Immunol. 64:283-350
52. 51. Rau R, Sander O, den Broeder A, et al. 1998. Long-term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum. 41:S55(Abstr.)
53. 52. Williams CA, Bloch DA, Sibley J, et al. 1996. Lymphoma and leukemia in rheumatoid arthritis: Are they associated with azathioprine, cyclophosphamide, or methotrexate? J. Clin. Rheum. 2:64-72
54. 53. Jones M, Symmons D, Finn J, Wolfe F. 1996. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br. J. Rheum. 35:738-45
55. 54. Baecklund E, Ekbom A, Sparen P, et al. 1998. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: a nested case-control study. BMJ 317:180-81
56. 55. Hannum CH, Wilcox CJ, Arend WP, et al. 1990. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336-40
57. 56. Campion GV, Lebsack ME, Lookabaugh J, et al. 1996. Dose-range and dose frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum. 39:1092-101
58. 57. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196-204
59. 58. Nuki G, Rozman B, Pavelka K, et al. 1997. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis. Arthritis Rheum. 40:S224 (Abstr.)
60. 59. Gabay C, Arend WP. 1998. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin. Immunopathol. 20:229-46
61. 60. Ghivizzani SC, Kang R, Muzzonigro T, et al. 1997. Gene therapy for arthritis: treatment of the first three patients. Arthritis Rheum. 40:S223 (Abstr.)
62. 61. Drevlow BE, Lovis R, Haag MA, et al. 1996. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 39:257-65
63. 62. Arend WP, Malyak M, Smith MF Jr, et al. 1994. Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J. Immunol. 153:4766-74
64. 63. Burger D, Chicheportiche R, Giri JG, Dayer J-M. 1995. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J. Clin. Invest. 96:38-41
65. 64. Ralph P, Nakoinz I, Sampson-Johannes A, et al. 1992. EL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J. Immunol. 148:808-14
66. 65. Vannier E, Miller LC, Dinarello CA. 1992. Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc. Natl. Acad. Sci. USA 89:4076-80
67. 66. Joyce DA, Gibbons D, Green P, et al. 1994. Two inhibitors of pro-inflammatory cytokine release, IL-10 and IL-4, have contrasting effects on release of soluble p75 TNF receptor by cultured monocytes. Eur. J. Immunol 24:2699-705
68. 67. Walmsley M, Katsikis PD, Abney E, et al. 1996. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 39: 495-503
69. 68. Maini RN, Paulus H, Breedveld FC, et al. 1997. rHuIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response study. Arthritis Rheum. 40:8224 (Abstr.)
70. 69. Joosten LA, Lubberts E, Durez P, et al. 1997. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum. 40: 249-60
71. 70. van den Bosch F, Russell A, Keystone EC, et al. 1998. rHuIL-4 in subjects with active rheumatoid arthritis (RA): a phase I dose escalating safely study. Arthritis Rheum. 41:S56 (Abstr.)
72. 71. Hermann J, Hall M, Maini R, et al. 1998. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 41:1388-97
73. 72. Walmsley M, Marinova-Mutafchieva L, Butler DM, Feldmann M. 1998. An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology 94:31-37
74. 73. Veys EM, Menkes CJ, Emery P. 1997. A randomised double-blind study comparing L4 treatment with recombinant interferon gamma versus placebo in the treatment of RA. Arthritis Rheum. 40: 62-68
75. 74. Tak PP, 't Hart BA, Kraan MC, et al. 1998. The effects of interferon beta treatment on arthritis. Arthritis Rheum. 41:S56 (Abstr.)
76. 75. Castell JV, Gomez-Lechon MJ, David M, et al. 1988. Recombinant human interleukin 6 (IL-6/BSF-2/HFS) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett. 232:347-50
77. 76. Tamura T, Udagawa N, Takahashi N, et al. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc. Natl. Acad. Sci. USA 90:11924-28
78. 77. Wendling D, Racadot E, Wijdenes J. 1993. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20:259-62
79. 78. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. 1998. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin. Immunopathol. 20:247-59